1. Academic Validation
  2. CT-721, a Potent Bcr-Abl Inhibitor, Exhibits Excellent In Vitro and In Vivo Efficacy in the Treatment of Chronic Myeloid Leukemia

CT-721, a Potent Bcr-Abl Inhibitor, Exhibits Excellent In Vitro and In Vivo Efficacy in the Treatment of Chronic Myeloid Leukemia

  • J Cancer. 2017 Aug 23;8(14):2774-2784. doi: 10.7150/jca.18731.
Yinghui Sun 1 Na Zhao 1 Huan Wang 1 Qiong Wu 1 Yunqi Han 1 Qichao Liu 1 Mangang Wu 1 Yuliang Liu 2 Fansheng Kong 3 He Wang 3 Ying Sun 3 Deguang Sun 2 Lutao Jing 2 Guojing Tang 2 Yuandong Hu 2 Dengming Xiao 2 Hong Luo 3 Yongxin Han 2 Yong Peng 1
Affiliations

Affiliations

  • 1 Department of Biology, Centaurus BioPharma Co., Ltd.
  • 2 Department of Medical Chemistry, Centaurus BioPharma Co., Ltd.
  • 3 Department of DMPK, Centaurus BioPharma Co., Ltd.
Abstract

Kinase inhibitors that target Bcr-Abl are highly effective in the treatment of chronic myeloid leukemia (CML). However, these inhibitors are often invalidated due to the drug resistance. Therefore, the discovery and development of novel Bcr-Abl inhibitors is required to overwhelm the drug resistance in the treatment of CML resistant to the currently used first-line Bcr-Abl inhibitors. Herein we have described a newly developed Bcr-Abl Inhibitor CT-721, which displayed potent inhibitory effects on wild-type and T315I mutant Bcr-Abl. It functioned as a typically ATP-competitive inhibitor, superior to other existing Bcr-Abl inhibitors. CT-721 also demonstrated time-dependent inhibition of Bcr-Abl activation and the resultant downstream signaling transduction pathways in Bcr-Abl positive cells. Furthermore, CT-721 induced cell Apoptosis and cell cycle arrest, and efficaciously inhibited tumor growth in Bcr-Abl-expressed K562 and KU812 xenograft models in a mechanism-based manner. Further PK/PD studies revealed a positive in vivo correlation between the compound concentration and inhibition of Bcr-Abl activity. Taken together, CT-721 is a potent and time-dependent Bcr-Abl kinase inhibitor, and has shown strong in vitro and in vivo anti-CML activities with a favorable pharmacokinetic profile, differentiating it from other Bcr-Abl kinase inhibitors already approved and current in development for the treatment of CML.

Keywords

Bcr-Abl; CT-721; anti-tumor; leukemia..

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-108704
    Bcr-Abl Inhibitor